– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology. – INB-01 may enable direct-to-brain delivery of various compounds in development across atai’s pipeline, with topline results expected in H1 2023. – Potential advantages may include ease of…


Previous articleSilo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics
Next articleatai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology